Stage IIIA Skin Melanoma Recruiting Phase 2 Trials for DB06186 (Ipilimumab)

IndicationStatusPhase
DBCOND0029533 (Stage IIIA Skin Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03033576Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by SurgeryTreatment